Detalhe da pesquisa
1.
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.
J Transl Med
; 21(1): 318, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37170241
2.
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
J Transl Med
; 21(1): 140, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36823670
3.
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.
J Transl Med
; 21(1): 610, 2023 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37684649
4.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880788
5.
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.
J Transl Med
; 20(1): 436, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180872
6.
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
J Transl Med
; 19(1): 132, 2021 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789686
7.
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
J Transl Med
; 19(1): 17, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33407577
8.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167578
9.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730009
10.
miR-579-3p controls melanoma progression and resistance to target therapy.
Proc Natl Acad Sci U S A
; 113(34): E5005-13, 2016 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503895
11.
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
J Transl Med
; 15(1): 244, 2017 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29202855
12.
The Dysregulation of the Monocyte-Dendritic Cell Interplay Is Associated with In-Hospital Mortality in COVID-19 Pneumonia.
J Clin Med
; 13(9)2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38731010
13.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Nat Commun
; 15(1): 146, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167503
14.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol
; 41(2): 212-221, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36049147
15.
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
Front Immunol
; 13: 962669, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36016960
16.
Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Front Immunol
; 13: 811131, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173725
17.
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36424033
18.
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies.
J Clin Med
; 10(21)2021 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34768455
19.
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Cancers (Basel)
; 13(16)2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34439318
20.
The Ratio of GrzB+ - FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma.
Cancers (Basel)
; 13(10)2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34066146